{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:48:57Z","timestamp":1765486137498},"reference-count":56,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"German Center for Infection Research (DZIF)"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.vaccine.2017.08.019","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T22:00:46Z","timestamp":1502748046000},"page":"5131-5139","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells"],"prefix":"10.1016","volume":"35","author":[{"given":"Ellen K.","family":"Link","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Brandm\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasemin","family":"Suezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Ameres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asisa","family":"Volz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Moosmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.08.019_b0005","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2017.08.019_b0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0015","doi-asserted-by":"crossref","first-page":"e1140","DOI":"10.1371\/journal.pntd.0001140","article-title":"Congenital cytomegalovirus mortality in the United States, 1990\u20132006","volume":"5","author":"Bristow","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.08.019_b0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1600-6143.2005.01207.x","article-title":"American Society of transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation","volume":"6","author":"Humar","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.vaccine.2017.08.019_b0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00430-015-0388-z","article-title":"The history of vaccination against cytomegalovirus","volume":"204","author":"Plotkin","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.molmed.2005.11.006","article-title":"Human cytomegalovirus vaccine: time to look for alternative options","volume":"12","author":"Khanna","year":"2006","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.vaccine.2017.08.019_b0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM198207013070102","article-title":"Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients","volume":"307","author":"Quinnan","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.08.019_b0040","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.08.019_b0045","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.08.019_b0050","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2002-08-2502","article-title":"Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease","volume":"101","author":"Gamadia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2017.08.019_b0055","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.08.019_b0060","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1128\/JVI.79.5.2869-2879.2005","article-title":"Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes","volume":"79","author":"Khan","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00005-007-0037-3","article-title":"The immunological burden of human cytomegalovirus infection","volume":"55","author":"Khan","year":"2007","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.vaccine.2017.08.019_b0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pep.2008.05.001","article-title":"Refinement in the production and purification of recombinant HCMV IE1-pp65 protein for the generation of epitope-specific T cell immunity","volume":"61","author":"Nguyen","year":"2008","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2017.08.019_b0075","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.humimm.2004.02.018","article-title":"Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells","volume":"65","author":"Rohrlich","year":"2004","journal-title":"Hum Immunol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/146532402317251482","article-title":"IE1-pp65 recombinant protein from human CMV combined with a nanoparticulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy","volume":"4","author":"Vaz-Santiago","year":"2002","journal-title":"Cytotherapy"},{"key":"10.1016\/j.vaccine.2017.08.019_b0085","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.vaccine.2006.09.067","article-title":"Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.019_b0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2008.04.034","article-title":"A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector","volume":"377","author":"Wang","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.08.019_b0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA","volume":"3","author":"Mayr","year":"1975","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2017.08.019_b0100","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0264-410X(94)90341-7","article-title":"A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus","volume":"12","author":"Sutter","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.019_b0105","doi-asserted-by":"crossref","first-page":"e1002557","DOI":"10.1371\/journal.ppat.1002557","article-title":"Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox","volume":"8","author":"Kremer","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.08.019_b0110","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat Commun"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2017.08.019_b0115","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0120","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line","volume":"238","author":"Carroll","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.08.019_b0125","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.019_b0130","doi-asserted-by":"crossref","unstructured":"Volz A, Sutter G. Modified Vaccinia virus Ankara: History, value in basic research, and current perspectives for vaccine development. Adv Virus Res 2017.","DOI":"10.1016\/bs.aivir.2016.07.001"},{"key":"10.1016\/j.vaccine.2017.08.019_b0135","doi-asserted-by":"crossref","first-page":"10444","DOI":"10.1128\/JVI.00833-08","article-title":"Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO","volume":"82","author":"Huh","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bbrc.2007.03.007","article-title":"N-terminal determinants of human cytomegalovirus IE1 protein in nuclear targeting and disrupting PML-associated subnuclear structures","volume":"356","author":"Lee","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2017.08.019_b0145","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1073\/pnas.0600007103","article-title":"A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling","volume":"103","author":"Paulus","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.019_b0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-61779-876-4_4","article-title":"Easy and efficient protocols for working with recombinant vaccinia virus MVA","volume":"890","author":"Kremer","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0155","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0264-410X(96)00072-2","article-title":"Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model","volume":"14","author":"Wyatt","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.019_b0160","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.019_b0165","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1128\/JVI.64.6.3108-3111.1990","article-title":"Transient dominant selection of recombinant vaccinia viruses","volume":"64","author":"Falkner","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0170","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s007050050303","article-title":"Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus","volume":"143","author":"Scheiflinger","year":"1998","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0175","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3109\/14653249.2010.549123","article-title":"Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells","volume":"13","author":"Flechsig","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.vaccine.2017.08.019_b0180","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1099\/vir.0.015347-0","volume":"91","author":"Backes","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0185","doi-asserted-by":"crossref","first-page":"e1004906","DOI":"10.1371\/journal.ppat.1004906","article-title":"Latent membrane protein LMP2A impairs recognition of EBV-infected cells by CD8+ T Cells","volume":"11","author":"Rancan","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.08.019_b0190","doi-asserted-by":"crossref","first-page":"e1464","DOI":"10.1371\/journal.pone.0001464","article-title":"Conditional immortalization of human B cells by CD40 ligation","volume":"3","author":"Wiesner","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.019_b0195","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.4049\/jimmunol.162.12.6959","article-title":"Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma","volume":"162","author":"Dunbar","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2017.08.019_b0205","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1002\/eji.200425463","article-title":"A mouse model of human adaptive immune functions: HLA-A2.1-\/HLA-DR1-transgenic H-2 class I-\/class II-knockout mice","volume":"34","author":"Pajot","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0210","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1128\/JVI.77.9.5226-5240.2003","article-title":"Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers","volume":"77","author":"Elkington","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0215","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1038\/srep03993","article-title":"Molecular imprint of exposure to naturally occurring genetic variants of human cytomegalovirus on the T cell repertoire","volume":"4","author":"Smith","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2017.08.019_b0220","doi-asserted-by":"crossref","first-page":"e1004512","DOI":"10.1371\/journal.ppat.1004512","article-title":"Crystal structure of cytomegalovirus IE1 protein reveals targeting of TRIM family member PML via coiled-coil interactions","volume":"10","author":"Scherer","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.08.019_b0225","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI119822","article-title":"CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy","volume":"100","author":"Schultze","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2017.08.019_b0230","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/eji.201242439","article-title":"Specific CD8(+) T cells recognize human herpesvirus 6B","volume":"42","author":"Martin","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0235","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.4049\/jimmunol.170.4.2030","article-title":"Modulation of HLA-A*0201-restricted T cell responses by natural polymorphism in the IE1(315\u2013324) epitope of human cytomegalovirus","volume":"170","author":"Prod'homme","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0240","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1128\/JVI.77.7.4457-4462.2003","article-title":"Use of transgenic HLA A*0201\/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response","volume":"77","author":"Gallez-Hawkins","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0245","first-page":"4955","article-title":"Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo","volume":"59","author":"Drexler","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2017.08.019_b0250","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1016\/j.vaccine.2013.06.073","article-title":"Poxvirus vectors","volume":"31","author":"Kreijtz","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.019_b0255","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.V78.5.1373.1373","article-title":"Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease","volume":"78","author":"Reusser","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2017.08.019_b0260","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3389\/fimmu.2015.00598","article-title":"A diverse repertoire of CD4 T cells targets the immediate-early 1 protein of human cytomegalovirus","volume":"6","author":"Ameres","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0265","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1128\/JVI.01633-16","article-title":"Increased protein degradation improves influenza virus nucleoprotein-specific CD8+ T cell activation in vitro but not in C57BL\/6 mice","volume":"90","author":"Altenburg","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0270","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1099\/jgv.0.000425","article-title":"Myristoylation increases the CD8+T-cell response to a GFP prototype antigen delivered by modified vaccinia virus Ankara","volume":"97","author":"Marr","year":"2016","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.08.019_b0275","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1089\/hum.2009.216","article-title":"Fusion of the human cytomegalovirus pp65 antigen with both ubiquitin and ornithine decarboxylase additively enhances antigen presentation to CD8(+) T cells in human dendritic cells","volume":"21","author":"Park","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2017.08.019_b0280","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood-2016-07-729756","article-title":"MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults","volume":"129","author":"La Rosa","year":"2017","journal-title":"Blood"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17310861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T02:16:42Z","timestamp":1692929802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17310861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":56,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0264410X17310861"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}